MediciNova, Inc.
4275 Executive Square
Suite 300
La Jolla, CA 92037
United States
858 373 1500
https://www.medicinova.com
版塊: Healthcare
行業: Biotechnology
全職員工: 13
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, CEO & Executive Director | 907.26k | 無 | 1950 |
| Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. | Chief Medical Officer & Director | 649.05k | 無 | 1966 |
| Mr. Jason J. Kruger CPA | CFO & Principal Financial Officer | 無 | 無 | 1978 |
| Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer | 無 | 無 | 1965 |
| Mr. John O'Neil CPA | Controller | 無 | 無 | 無 |
描述
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
公司管治
截至 2024年5月1日 止，MediciNova, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：10；股東權利：5；現金賠償：7。
